scanx.trade

Zydus Lifesciences Q1FY27 revenue rises 22% with 24.1% EBITDA margin

Zydus Lifesciences logoZydus Lifesciences
Sig1.90Sen-0.80Env0.00Soc0.00Gov0.00

Zydus Lifesciences reported Q1FY27 revenue up 22% to ₹80.2 billion and EBITDA of ₹19.3 billion with a 24.1% margin. Net profit fell to ₹9,398 million from ₹14,668 million a year earlier. The Board approved the results on August 11, 2026. Branded formulations grew 20%, international formulations rose 34%, and US generics filed five ANDAs and launched 11 products. Management reaffirmed strong double-digit FY27 growth.

Coverage (1)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro